Seattle, WA– April 1, 2022– Keya Medical announced that DEEPVESSEL FFR (DVFFR), has been cleared by U.S. Food and Drug Administration (FDA).
Keya Medical’s computer scientists, working with colleagues at the Shenzhen Second People’s Hospital, have devised a new method that significantly boosts segmentation accuracy and performance.
GAIR2021 released the annual Best AI Digital Intelligence List. In the medical field, Keya Medical received the Best Clinical Aided Decision-Making Product Award for its flagship product DeepVessel FFR.
The 2021 AHA/ACC Guideline for the Evaluation and Diagnosis of Chest Pain was released on 28 October 2021. This report represents years of work by the Joint Committee on Clinical Practice Guidelines to define protocols and algorithms based on the evidence.
On August 24, Keya Medical’s flagship product, DeepVessel FFR, was successfully implemented in Beijing Anzhen Hospital.
Recent Comments